Product Description
Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperkinetic movement disorder, Huntington's disease. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28742396/)
Mechanisms of Action: VMAT2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Chorea|Huntington Disease *
Approval Status: Approved
Approved Countries: Indonesia | Japan | Malaysia | Singapore | United States
Approved Indications: None
Known Adverse Events: None
Company: Neurocrine
Company Location: Western America
Company Founding Year: 1992
Additional Commercial Interests: Mitsubishi Tanabe
Clinical Description
Countries in Clinic: Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Germany, Israel, Italy, Mexico, Poland, Portugal, Romania, Serbia, Slovakia, Spain, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Neurocrine presented P2 Tardive Dyskinesia results on 2026-01-15 for Valbenazine
- Clinical Outcomes Reported - Neurocrine presented P3 Cerebral Palsy results on 2025-12-22 for Valbenazine
- Clinical Outcomes Reported - Neurocrine presented P3 Huntington Disease results on 2025-10-06 for Valbenazine
Highest Development Phases
Phase 3: Chorea|Huntington Disease|Paralysis|Schizophrenia
Phase 2: Dystonia|Dystonic Disorders|Obsessive-Compulsive Disorder|Torticollis|Trichotillomania
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07111988 |
IRB25-0568 | P2 |
Not yet recruiting |
Obsessive-Compulsive Disorder |
2027-12-01 |
12% |
2025-12-16 |
|
NCT05207085 |
NCT05207085 | P2 |
Recruiting |
Trichotillomania |
2027-02-15 |
12% |
2026-02-04 |
|
NCT06771323 |
HM20029848 | P2 |
Recruiting |
Dystonic Disorders|Dystonia|Torticollis |
2026-01-01 |
12% |
2025-04-05 |
|
NCT04400331 |
NBI-98854-HD3006 | P3 |
Active, not recruiting |
Chorea|Huntington Disease |
2026-03-01 |
32% |
2023-12-30 |
Primary Completion Date|Primary Endpoints |
NCT05206513 |
NBI-98854-DCP3018 | P3 |
Active, not recruiting |
Dyskinesias|Cerebral Palsy|Paralysis |
2025-12-01 |
19% |
2025-08-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05110157 |
Journey Study | P3 |
Completed |
Schizophrenia |
2025-02-04 |
30% |
2025-07-11 |
|
NCT06312189 |
NBI-98854-HD3022 | P3 |
Enrolling by invitation |
Huntington Disease|Chorea |
2026-04-01 |
6% |
2024-05-17 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
2022-502713-29-00 |
NBI-98854-DCP3018 | P3 |
Recruiting |
Cerebral Palsy |
2026-01-16 |
2025-05-02 |
Treatments |
|
2023-508433-14-00 |
NBI-98854-ATS3019 | P3 |
Completed |
Schizophrenia |
2025-02-11 |
2025-05-02 |
Treatments |
|
2022-502233-25-00 |
NBI-98854-ATS3020 | P3 |
Completed |
Schizophrenia |
2023-11-08 |
2025-05-02 |
Treatments |